Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.72 |
| ▸ | ITGAV | P06756 | 20/20 | 0.72 |
| ▸ | ITGB5 | P18084 | 20/20 | 0.72 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20305086 | 1.00 | ITGB3 (0.72) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL19384515 | 0.85 | ITGAV (0.65) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL17640900 | 0.85 | ITGAV (0.65) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL19399826 | 0.85 | ITGB3 (0.67) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL19404121 | 0.84 | ITGB3 (0.60) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL23308999 | 0.83 | ITGAV (0.59) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL17629343 | 0.83 | ITGB3 (0.60) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL30822031 | 0.83 | ITGB3 (0.60) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL29744295 | 0.82 | ITGAV (0.62) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL20141850 | 0.82 | ITGAV (0.57) | ITGB3ITGAVITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043421-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2024-02-08 | — | — | US | disclosed |
| US-20210122747-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2021-04-29 | — | — | US | disclosed |
| US-10696672-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3197895-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-03-11 | — | — | EP | disclosed |
| EP-3558303-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190322663-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2019-10-24 | — | — | US | disclosed |
| WO-2018119087-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-3197895-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046241-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043421-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGB7 | ITGB3 10/4885ITGAV 8/4885ITGB5 11/4885 |
| US-10696672-B2 | Amino acid compounds and methods of use | ITGB6, ITGA6, ITGA5 | ITGB3 13/4885ITGAV 4/4885ITGB5 9/4885 |
| US-20210122747-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGAV | ITGB3 13/4885ITGAV 3/4885ITGB5 9/4885 |
| US-20190322663-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | ITGB3 13/4885ITGAV 4/4885ITGB5 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.